Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:04 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076536
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Operating expenses: | |||
| Cost of product sales | 6,970 | 826 | — |
| Research and development | 258,784 | 241,647 | 163,032 |
| Selling, general and administrative | 179,682 | 120,879 | 66,922 |
| Total operating expenses | 445,436 | 363,352 | 229,954 |
| Loss from operations | (273,084) | (339,672) | (229,954) |
| Other (expense) income, net: | |||
| Royalty interest expense | (33,779) | (4,930) | — |
Item 16. Form 10-K Summary
FAQ
- What is Syndax Pharmaceuticals's SG&A?
- Syndax Pharmaceuticals (SNDX) reported SG&A of $44.92M in Q4 2025.
- How has Syndax Pharmaceuticals's SG&A changed year-over-year?
- Syndax Pharmaceuticals's SG&A increased by 48.6% year-over-year, from $30.22M to $44.92M.
- What is the long-term trend for Syndax Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's SG&A has grown at a 63.3% compound annual growth rate (CAGR), from $25.24M to $179.68M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Syndax Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude